Boston Sci climbs on FDA approval, amid warning letter (Market Watch)
Boston Scientific shares trade higher as the Food and Drug Administration issued new approvals for its Taxus coronary-stent system, despite an outstanding agency warning letter than generally precludes such approvals.

FDA Warns Companies To Stop Marketing Unapproved Ophthalmic Balanced Salt Solution Drug Products And Topical Drug ... (Medical News Today)
The U.S. Food and Drug Administration (FDA) announced that companies marketing unapproved ophthalmic balanced salt solutions (BSS) and unapproved topical drug products containing papain must stop manufacturing and marketing these products or risk enforcement action. FDA is taking these actions because it has received reports of serious adverse events associated with their uses.